Biogen Breaks Above 200-Day Moving Average - Bullish for BIIB

Claudine Rigal
Juillet 18, 2017

In recent trading action Biogen Inc. Thompson Siegel & Walmsley LLC now owns 408 shares of the biotechnology company's stock worth $116,000 after buying an additional 12 shares in the last quarter. Burney Co.'s holdings in Biogen were worth $3,025,000 at the end of the most recent quarter.

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Clearbridge Investments LLC raised its position in shares of Biogen by 4.0% in the first quarter. BlackRock Inc. raised its position in shares of Biogen by 2,762.0% in the first quarter. Capital Guardian Trust Co. now owns 359 shares of the biotechnology company's stock valued at $102,000 after buying an additional 203 shares during the last quarter. Wrapmanager Inc. raised its position in Biogen by 7.7% in the first quarter.

Biogen Inc. (NASDAQ:BIIB) has received a consensus recommendation of "Buy" from the thirty ratings firms that are now covering the stock, reports. Capital Analysts LLC increased its stake in shares of Biogen by 1.4% in the fourth quarter. Wrapmanager Inc. now owns 5,525 shares of the biotechnology company's stock worth $1,511,000 after buying an additional 396 shares in the last quarter. Finally, Thompson Siegel & Walmsley LLC increased its stake in shares of Biogen by 3.0% in the fourth quarter. Biogen Inc. has a one year low of $234.11 and a one year high of $307.76.

Biogen (NASDAQ BIIB) traded up 0.66% during midday trading on Thursday, reaching $282.65. 1,531,778 shares of the company were exchanged. Biogen Inc. The stock's 50-day moving average is $259.24 and its 200-day moving average is $274.78. The stock has a market cap of $59.95 billion, a price-to-earnings ratio of 17.70 and a beta of 0.77.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Tuesday, April 25th. The biotechnology company reported $5.20 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $4.97 by $0.23.

For a total return analysis, there is the 21.00% return on equity and the 29.50% return on assets to consider. The business had revenue of $2.81 billion for the quarter, compared to analysts' expectations of $2.73 billion. During the same quarter in the prior year, the company earned $4.79 EPS. Zooming in closer, company stock has been 3.14% for the quarter, 10.83% over the past month, and 3.32% over the past week. Biogen presently has an average rating of Buy and a consensus target price of $327.72.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & global copyright legislation. The original version of this piece of content can be accessed at

Several research firms have recently issued reports on BIIB. Argus Research maintained it with "Buy" rating and $360 target in Monday, July 27 report. Piper Jaffray Companies set a $442.00 target price on shares of Biogen and gave the company a "buy" rating in a research note on Monday, May 15th. Credit Suisse Group reaffirmed a "neutral" rating and set a $296.00 target price on shares of Biogen in a research report on Monday, April 3rd. Finally, Sanford C. Bernstein reaffirmed an "outperform" rating and issued a $310.00 price objective on shares of Biogen in a research report on Tuesday, April 25th. On September 6 the company was changed to a "Hold" according to a Jefferies report which is down from the previous "Buy" rating.

In other news, Director Brian S. Posner sold 1,084 shares of Biogen stock in a transaction that occurred on Friday, June 9th. The share price has moved forward from its 20 days moving average, trading at a distance of 2.9% and stays 3.14% away from its 50 days moving average. Following the transaction, the vice president now owns 10,813 shares of the company's stock, valued at $3,135,770. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Alexander J. Denner bought 73,858 shares of the business's stock in a transaction on Thursday, April 27th. The stock was bought at an average price of $271.35 per share, with a total value of $380,432.70. The disclosure for this purchase can be found here.

D'autres rapports CampDesrEcrues

Discuter de cet article